Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System
US 9,163,256 In forceTerm ends Jan 1, 2029 · Medium confidence
20-year base term ended Apr 29, 2025
Why Medium: A parent in the chain could not be resolved.
Apr 29, 2005
Jan 1, 2029
Oct 20, 2015
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 29, 2005, when the earliest non-provisional application in its chain was filed (this one was filed Aug 20, 2007); a parent in its chain could not be resolved (the next row) | Apr 29, 2025 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +1343 days, USPTO patent term adjustment record | Jan 1, 2029 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 1, 2029 | Medium confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.